Trial Outcomes & Findings for A Study of LY3006072 in Healthy Participants (NCT NCT01640249)
NCT ID: NCT01640249
Last Updated: 2019-08-08
Results Overview
AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.
Recruitment status
TERMINATED
Study phase
PHASE1
Target enrollment
18 participants
Primary outcome timeframe
Baseline, up to 21 days
Results posted on
2019-08-08
Participant Flow
This was a 2-part (Part A and Part B) crossover study. Part A was a dose-escalation with up to 3-period crossover with 2 alternating cohorts (Cohorts 1 and 2). There was 14 days of washout time between each dose. Part B was not initiated as study was terminated early due to technical factors.
Participant milestones
| Measure |
Cohort 1 (Sequence 1)
Participants received LY3006072 and Placebo capsules as per below dosing schedules.
Period 1: 1 milligrams (mg) LY3006072, Period 2: 10 mg LY3006072 and Period 3: Placebo
|
Cohort 1 (Sequence 2)
Participants received LY3006072 and Placebo capsules as per below dosing schedules.
Period 1: 1 mg LY3006072, Period 2: Placebo, Period 3: 40 mg LY3006072
|
Cohort 1 Sequence 3
Participants received LY3006072 and Placebo capsules as per below dosing schedule.
Period 1: Placebo, Period 2: 10 mg LY3006072 and Period 3: 40 mg LY3006072
|
Cohort 1 Sequence 4
Participants received 1 mg, 10 mg and 40 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 1 mg LY3006072, Period 2: 10 mg LY3006072 and Period 3: 40 mg LY3006072
|
Cohort 2 (Sequence 1)
Participants received Placebo and 20 mg of LY3006072 capsules as per below dosing schedule.
Period 1: Placebo and Period 2: 20 mg LY3006072
|
Cohort 2 (Sequence 2)
Participants received 3 mg and 20 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 3 mg LY3006072 and Period 2: 20 mg LY3006072
|
Cohort 2 (Sequence 3)
Participants received Placebo and 3 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 3 mg LY3006072 and Period 2: Placebo
|
|---|---|---|---|---|---|---|---|
|
Period 1
STARTED
|
3
|
2
|
2
|
2
|
2
|
5
|
2
|
|
Period 1
Received at Least 1 Dose of Study Drug
|
3
|
2
|
2
|
2
|
2
|
5
|
2
|
|
Period 1
COMPLETED
|
2
|
2
|
2
|
2
|
2
|
4
|
2
|
|
Period 1
NOT COMPLETED
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
|
Period 2
STARTED
|
2
|
2
|
2
|
2
|
2
|
4
|
2
|
|
Period 2
COMPLETED
|
2
|
2
|
2
|
2
|
2
|
4
|
2
|
|
Period 2
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Period 3
STARTED
|
2
|
2
|
2
|
2
|
0
|
0
|
0
|
|
Period 3
COMPLETED
|
2
|
2
|
2
|
1
|
0
|
0
|
0
|
|
Period 3
NOT COMPLETED
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
Cohort 1 (Sequence 1)
Participants received LY3006072 and Placebo capsules as per below dosing schedules.
Period 1: 1 milligrams (mg) LY3006072, Period 2: 10 mg LY3006072 and Period 3: Placebo
|
Cohort 1 (Sequence 2)
Participants received LY3006072 and Placebo capsules as per below dosing schedules.
Period 1: 1 mg LY3006072, Period 2: Placebo, Period 3: 40 mg LY3006072
|
Cohort 1 Sequence 3
Participants received LY3006072 and Placebo capsules as per below dosing schedule.
Period 1: Placebo, Period 2: 10 mg LY3006072 and Period 3: 40 mg LY3006072
|
Cohort 1 Sequence 4
Participants received 1 mg, 10 mg and 40 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 1 mg LY3006072, Period 2: 10 mg LY3006072 and Period 3: 40 mg LY3006072
|
Cohort 2 (Sequence 1)
Participants received Placebo and 20 mg of LY3006072 capsules as per below dosing schedule.
Period 1: Placebo and Period 2: 20 mg LY3006072
|
Cohort 2 (Sequence 2)
Participants received 3 mg and 20 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 3 mg LY3006072 and Period 2: 20 mg LY3006072
|
Cohort 2 (Sequence 3)
Participants received Placebo and 3 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 3 mg LY3006072 and Period 2: Placebo
|
|---|---|---|---|---|---|---|---|
|
Period 1
Withdrawal by Subject
|
1
|
0
|
0
|
0
|
0
|
1
|
0
|
Baseline Characteristics
A Study of LY3006072 in Healthy Participants
Baseline characteristics by cohort
| Measure |
Cohort 2 (Sequence 2)
n=5 Participants
Participants received 3 mg and 20 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 3 mg LY3006072 and Period 2: 20 mg LY3006072
|
Cohort 2 (Sequence 3)
n=2 Participants
Participants received Placebo and 3 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 3 mg LY3006072 and Period 2: Placebo
|
Cohort 1 (Sequence 1)
n=3 Participants
Participants received LY3006072 and Placebo capsules as per below dosing schedules.
Period 1: 1 milligrams (mg) LY3006072, Period 2: 10 mg LY3006072 and Period 3: Placebo
|
Cohort 1 (Sequence 2)
n=2 Participants
Participants received LY3006072 and Placebo capsules as per below dosing schedules.
Period 1: 1 mg LY3006072, Period 2: Placebo, Period 3: 40 mg LY3006072
|
Cohort 1 (Sequence 3)
n=2 Participants
Participants received LY3006072 and Placebo capsules as per below dosing schedule.
Period 1: Placebo, Period 2: 10 mg LY3006072 and Period 3: 40 mg LY3006072
|
Cohort 1 (Sequence 4)
n=2 Participants
Participants received 1 mg, 10 mg and 40 mg of LY3006072 capsules as per below dosing schedule.
Period 1: 1 mg LY3006072, Period 2: 10 mg LY3006072 and Period 3: 40 mg LY3006072
|
Cohort 2 (Sequence 1)
n=2 Participants
Participants received Placebo and 20 mg of LY3006072 capsules as per below dosing schedule.
Period 1: Placebo and Period 2: 20 mg LY3006072
|
Total
n=18 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
3 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
10 Participants
n=6 Participants
|
|
Age, Categorical
>=65 years
|
2 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
8 Participants
n=6 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
12 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
3 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
2 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
6 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
5 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
18 Participants
n=6 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
2 Participants
n=6 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
16 Participants
n=6 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=30 Participants
|
0 Participants
n=3 Participants
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=31 Participants
|
0 Participants
n=6 Participants
|
|
Region of Enrollment
United States
|
5 Participants
n=30 Participants
|
2 Participants
n=3 Participants
|
3 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
2 Participants
n=7 Participants
|
2 Participants
n=31 Participants
|
18 Participants
n=6 Participants
|
PRIMARY outcome
Timeframe: Baseline, up to 21 daysPopulation: All randomized participants who received at least one dose of study drug.
AEs that were considered possibly related to study drug, in the opinion of the investigator, were reported. A summary of serious and all other non-serious AEs, regardless of possible drug relatedness, is located in the Reported Adverse Event module.
Outcome measures
| Measure |
Placebo
n=9 Participants
Participants received placebo capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
1 mg LY3006072
n=6 Participants
Participants received 1 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
3 mg LY3006072
n=6 Participants
Participants received 3 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
10 mg LY3006072
n=6 Participants
Participants received 10 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
20 mg LY3006072
n=6 Participants
Participants received 20 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
40 mg LY3006072
n=6 Participants
Participants received 40 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
|---|---|---|---|---|---|---|
|
Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AEs
Serious AEs
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
|
Number of Participants With One or More Drug Related Adverse Events (AEs) or Any Serious AEs
Other Non-Serious AEs
|
0 Participants
|
3 Participants
|
1 Participants
|
1 Participants
|
2 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Predose, 0.25, 0.5, 1, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 96 hours postdosePopulation: All randomized participants who received at least one dose of study drug and have evaluable PK data.
Outcome measures
| Measure |
Placebo
n=6 Participants
Participants received placebo capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
1 mg LY3006072
n=6 Participants
Participants received 1 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
3 mg LY3006072
n=6 Participants
Participants received 3 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
10 mg LY3006072
n=6 Participants
Participants received 10 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
20 mg LY3006072
n=6 Participants
Participants received 20 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
40 mg LY3006072
Participants received 40 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
|---|---|---|---|---|---|---|
|
Pharmacokinetics: Maximum Concentration (Cmax) of LY3006072
|
18.8 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 20
|
57.0 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 12
|
160 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 24
|
263 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 42
|
576 nanograms per milliliter (ng/mL)
Geometric Coefficient of Variation 31
|
—
|
SECONDARY outcome
Timeframe: Predose, 0.25, 0.5, 1, 2, 3, 5, 8, 12, 16, 24, 36, 48 and 96 hours postdosePopulation: All randomized participants who received at least one dose of study drug and have evaluable PK data.
PK: Area Under the Concentration-Time Curve from Time Zero to Infinity (AUC\[0-inf\] of LY3006072.
Outcome measures
| Measure |
Placebo
n=6 Participants
Participants received placebo capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
1 mg LY3006072
n=6 Participants
Participants received 1 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
3 mg LY3006072
n=6 Participants
Participants received 3 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
10 mg LY3006072
n=6 Participants
Participants received 10 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
20 mg LY3006072
n=6 Participants
Participants received 20 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
40 mg LY3006072
Participants received 40 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
|---|---|---|---|---|---|---|
|
Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY3006072
|
1530 nanograms * hours per mL (ng*hr/mL)
Geometric Coefficient of Variation 47
|
4800 nanograms * hours per mL (ng*hr/mL)
Geometric Coefficient of Variation 34
|
14400 nanograms * hours per mL (ng*hr/mL)
Geometric Coefficient of Variation 25
|
24700 nanograms * hours per mL (ng*hr/mL)
Geometric Coefficient of Variation 27
|
65600 nanograms * hours per mL (ng*hr/mL)
Geometric Coefficient of Variation 21
|
—
|
Adverse Events
Placebo
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
1 mg LY3006072
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
3 mg LY3006072
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
10 mg LY3006072
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
20 mg LY3006072
Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths
40 mg LY3006072
Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Placebo
n=9 participants at risk
Participants received placebo capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
1 mg LY3006072
n=6 participants at risk
Participants received 1 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
3 mg LY3006072
n=6 participants at risk
Participants received 3 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
10 mg LY3006072
n=6 participants at risk
Participants received 10 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
20 mg LY3006072
n=6 participants at risk
Participants received 20 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
40 mg LY3006072
n=6 participants at risk
Participants received 40 mg LY3006072 capsule orally with approximately 200 to 300 mL of room temperature water in the morning.
|
|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
50.0%
3/6 • Number of events 3 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
100.0%
6/6 • Number of events 6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/9 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
16.7%
1/6 • Number of events 1 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
0.00%
0/6 • Up To 21 Days
All randomized participants who received at least one dose of study drug.
|
Additional Information
Chief Medical Officer
Eli Lilly and Company
Phone: 800-545-5979
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60